Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension is characterized by residual tissue clots that block the pulmonary vasculature 1, leading to increased pulmonary vascular resistance, progressive pulmonary hypertension, and right ventricular failure. Patients with chronic thromboembolic pulmonary hypertension have a poor prognosis unless they receive early treatment.

  • Pulmonary endarterectomy
  • chronic thromboembolic

Related Conference of Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

January 25-26, 2024

39th World Cardiology Conference

London, UK
February 08-09, 2024

3rd International Conference on Cardiology

Paris, France
March 07-08, 2024

38th World Congress on Heart Diseases

Toronto, Canada
March 11-12, 2024

13th World Heart Congress

Paris, France
May 30-31, 2024

6th Euro Cardiology Congress

Vienna, Austria
May 30-31, 2024

39th World Congress on Heart Diseases

Vienna, Austria
June 20-21, 2024

5th European Summit on Cardiology Research

Dublin, Ireland
July 16-17, 2024

13th World Heart Congress

Paris, France

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in